Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Disease

Dc Cardioversion

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 20, 2026 · PHASE 4 TRIAL

Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

ClinicalTrials.gov

This is a registered clinical trial currently recruiting with no results posted; it represents a planned Phase 4 study addressing an understudied question about SGLT2 inhibitors and rhythm maintenance post-cardioversion.

PreliminarySamsung Medical Center SGLT2 Inhibitor Dc Cardioversion

Reported

Planned enrollment200

Randomization ratio1:1

Primary outcome measureRecurrence of atrial tachyarrhythmia, 1 mon…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support